Bevacizumab in extensive-disease small cell lung cancer: the search continues

The outcomes of extended stage small cell lung cancer (ED-SCLC) have remained unchanged over the past two decades, with a median survival of 10 months and a 2-year survival of 10%, despite addition of radiation therapy to certain subsets of patients (1). The combination chemotherapy with cisplatin and etoposide has remained unchanged since the late 1990’s (2), despite testing multiple different agents, both cytotoxic and targeted agents